Dr. McGregor on the Evolving Treatment Landscape of RCC


In Partnership With:

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the evolving treatment landscape of renal cell carcinoma (RCC).

The field is expanding to evaluate new pathways, targets, and combination therapies to improve outcomes for patients with RCC, McGregor explains.

Historically, the treatment paradigm was limited until the advent of TKIs, says McGregor. Moreover, the addition of cabozantinib (Cabometyx) to the second-line setting was important as the agent demonstrated a survival benefit versus sunitinib (Sutent).

Additionally, nivolumab (Opdivo) has been a welcomed addition to the armamentarium, McGregor continues.

In the frontline setting, multiple combination regimens, including nivolumab plus ipilimumab (Yervoy), have demonstrated overall survival benefit compared with TKI monotherapy, concludes McGregor.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Martin H. Voss, MD, an expert on renal cell carcinoma
Laurence Albigès, MD, PhD, an expert on renal cell carcinoma